Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Lyvgen to Start Phase II Trial of mAb with BMS’s PD-1 Keytruda

publication date: Nov 28, 2022

Shanghai Lyvgen Biopharma announced plans to start a China Phase II combination trial of LVGN7409 and Bristol Myers Squibb’s Opdivo (nivolumab), a PD-1 drug. The trial will enroll patients with advanced/metastatic non-small cell lung cancer (NSCLC). Lyvgen’s next-gen CD40 agonistic monoclonal antibody is designed to induce T cell by increasing tumor antigen presentation and activate the tumor microenvironment. Lyvgen’s proprietary xLinkAb platform generates agonistic antibodies designed to produce immunostimulatory activity localized in tumors More details....

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital